nach oben

Familial Cancer

Erschienen in:

01.06.2013 | Original Article

Chemotherapy of MMR-deficient colorectal cancer

verfasst von: N. Devaud, S. Gallinger

Erschienen in: Familial Cancer | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer (CRC) continues to rank as the third most common cancer in Western society and the second leading cause of cancer death in North America. There are at least three distinct, and relatively discreet, molecular pathways associated with this disease: chromosomal instability (CIN), microsatellite instability (MSI) and the cytosine polyguanine island methylator phenotype. Defects in the DNA mismatch repair system (MMR) account for the MSI phenotype and genotype of about 15 % of CRC. Although high frequency MSI tumors have better stage independent prognosis compared to those with CIN, MMR deficient CRC appears to be resistant to fluorouracil based treatment, but sensitive to other therapeutic regimens. This review summarises current literature on differential chemosensitivity of MMR-deficient CRC.

Landis SH et al (1999) Cancer statistics. CA Cancer J Clin 49(1):8–31, 1

Lynch HT (1985) Classics in oncology. Aldred Scott Warthin, M.D., Ph.D (1866–1931). CA Cancer J Clin 35(6):345–347

Lynch HT et al (1993) Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review. Gastroenterology 104(5):1535–1549PubMed

Fishel R et al (1993) The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75(5):1027–1038PubMedCrossRef

Leach FS et al (1993) Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75(6):1215–1225PubMedCrossRef

Peltomaki P et al (1993) Genetic mapping of a locus predisposing to human colorectal cancer. Science 260(5109):810–812PubMedCrossRef

Nishisho I et al (1991) Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253(5020):665–669PubMedCrossRef

Parsons R et al (1995) Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res 55(23):5548–5550PubMed

Rampino N et al (1997) Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science 275(5302):967–969PubMedCrossRef

10.

de la Chapelle A, Hampel H (2010) Clinical relevance of microsatellite instability in colorectal cancer. J Clin Oncol 28(20):3380–3387PubMedCrossRef

11.

Lindor NM et al (2002) Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 20(4):1043–1048PubMedCrossRef

12.

Boland CR et al (1998) A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 58(22):5248–5257PubMed

13.

Poynter JN et al (2008) Molecular characterization of MSI-H colorectal cancer by MLHI promoter methylation, immunohistochemistry, and mismatch repair germline mutation screening. Cancer Epidemiol Biomarkers Prev 17(11):3208–3215PubMedCrossRef

14.

Sinicrope FA (2010) DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol 7(3):174–177PubMedCrossRef

15.

Jass JR et al (1998) Morphology of sporadic colorectal cancer with DNA replication errors. Gut 42(5):673–679PubMedCrossRef

16.

Thibodeau SN, Bren G, Schaid D (1993) Microsatellite instability in cancer of the proximal colon. Science 260(5109):816–819PubMedCrossRef

17.

Lanza G et al (2006) Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 24(15):2359–2367PubMedCrossRef

18.

Sinicrope FA et al (2006) Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131(3):729–737PubMedCrossRef

19.

Samowitz WS et al (2001) Microsatellite instability in sporadic colon cancer is associated with an improved prognosis at the population level. Cancer Epidemiol Biomarkers Prev 10(9):917–923PubMed

20.

Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23(3):609–618PubMedCrossRef

21.

Gryfe R et al (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342(2):69–77PubMedCrossRef

22.

Hutchins G et al (2011) Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 29(10):1261–1270PubMedCrossRef

23.

Moertel CG et al (1990) Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 322(6):352–358PubMedCrossRef

24.

O’Connell MJ et al (1998) Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 16(1):295–300PubMed

25.

Wolmark N et al (1993) The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 11(10):1879–1887PubMed

26.

Wolmark N et al (1999) Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 17(11):3553–3559PubMed

27.

Andre T et al (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343–2351PubMedCrossRef

28.

Kuebler JP et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25(16):2198–2204PubMedCrossRef

29.

Andre T et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116PubMedCrossRef

30.

Ribic CM et al (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349(3):247–257PubMedCrossRef

31.

Benson AB 3rd et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22(16):3408–3419PubMedCrossRef

32.

Kim GP et al (2007) Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol 25(7):767–772PubMedCrossRef

33.

Elsaleh H et al (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355(9217):1745–1750PubMedCrossRef

34.

Hemminki A et al (2000) Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 119(4):921–928PubMedCrossRef

35.

Sargent DJ et al (2010) Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 28(20):3219–3226PubMedCrossRef

36.

Meyers M et al (2001) Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 61(13):5193–5201PubMed

37.

Arnold CN, Goel A, Boland CR (2003) Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer 106(1):66–73PubMedCrossRef

38.

Pocard M et al (2000) Response to 5-fluorouracil of orthotopically xenografted human colon cancers with a microsatellite instability: influence of P53 status. Anticancer Res 20(1A):85–90PubMed

39.

Parker WB, Cheng YC (1990) Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 48(3):381–395PubMedCrossRef

40.

Nehme A et al (1997) Differential induction of c-Jun NH2-terminal kinase and c-Abl kinase in DNA mismatch repair-proficient and -deficient cells exposed to cisplatin. Cancer Res 57(15):3253–3257PubMed

41.

Fink D et al (1997) In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 57(10):1841–1845PubMed

42.

des Guetz G et al (2007) Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer. Anticancer Res 27(4C):2715–2719PubMed

43.

Kim ST et al (2010) Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 66(4):659–667PubMedCrossRef

44.

Kim ST et al (2010) The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol 27(4):1277–1285PubMedCrossRef

45.

Zaanan A et al (2010) Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol 21(4):772–780PubMedCrossRef

46.

Jacob S et al (2001) The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 61(17):6555–6562PubMed

47.

Magrini R et al (2002) Cellular effects of CPT-11 on colon carcinoma cells: dependence on p53 and hMLH1 status. Int J Cancer 101(1):23–31PubMedCrossRef

48.

Charara M et al (2004) Microsatellite status and cell cycle associated markers in rectal cancer patients undergoing a combined regimen of 5-FU and CPT-11 chemotherapy and radiotherapy. Anticancer Res 24(5B):3161–3167PubMed

49.

Fallik D et al (2003) Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res 63(18):5738–5744PubMed

50.

Vincent F et al (2009) Angiotensinogen delays angiogenesis and tumor growth of hepatocarcinoma in transgenic mice. Cancer Res 69(7):2853–2860PubMedCrossRef

51.

Bolderson E et al (2004) ATM is required for the cellular response to thymidine induced replication fork stress. Hum Mol Genet 13(23):2937–2945PubMedCrossRef

52.

Martin SA et al (2009) Methotrexate induces oxidative DNA damage and is selectively lethal to tumour cells with defects in the DNA mismatch repair gene MSH2. EMBO Mol Med 1(6–7):323–337PubMedCrossRef

Titel: Chemotherapy of MMR-deficient colorectal cancer
verfasst von: N. Devaud
S. Gallinger
Publikationsdatum: 01.06.2013
Verlag: Springer Netherlands
Erschienen in: Familial Cancer / Ausgabe 2/2013
Print ISSN: 1389-9600
Elektronische ISSN: 1573-7292
DOI: https://doi.org/10.1007/s10689-013-9633-z

Springer Medizin

Chemotherapy of MMR-deficient colorectal cancer

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2013

Do lifestyle factors influence colorectal cancer risk in Lynch syndrome?

Prediction models in Lynch syndrome

Lynch syndrome-associated neoplasms: a discussion on histopathology and immunohistochemistry

The role of epigenetics in Lynch syndrome

The History of Lynch Syndrome

Genetic modifiers of cancer risk in Lynch syndrome: a review

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie